All
Make Valentine's Day special with these cards
Upcoming lung cancer webinar
New therapy regimen approved for advanced follicular lymphoma
CURE wins awards because of you
A letter to my cancer
I don't know anything about cancer
Study to ease cancer-related distress needs survivors
Chemotherapy shortage: A symptom of a bigger problem
Giving up my hair
Death panels, advance directives and end of life
Cancer and Careers' updates workbook
2010's Top 10 Cancer Stories
Do you make new year's resolutions?
Rituxan May Replace Watch and Wait for Patients with Asymptomatic Follicular Lymphoma
Researchers showed that patients with nonsymptomatic, advanced follicular lymphoma (FL) benefit from Rituxan (rituximab) over watchful waiting.
Istodax Shows Benefit in T-Cell Lymphomas
A phase 2 trial presented at the American Society of Hematology in December could pave the way for a second approval for Istodax (romidepsin).
Phase 1 Trial of Ponatinib Shows Early Success in CML
Study shows experimental drug ponatinib acts against a mutation found in small percentage of chronic myeloid leukemia cases that is resistant to other forms of therapy
Pediatric Regimen Better for Young Adults with AML
Treatment differs for Acute myeloid leukemia pediatric patients compared with older adults.
Bosutinib Joins Crowd of CML-Focused Drugs
Chronic myeloid leukemia (CML)usually can be managed as a chronic disease by therapies, including Gleevec (imatinib) or two newer drugs, Sprycel (dasatinib) or Tasigna (nilotinib).
Getting well: Cancer rehab
Exciting data released at ASH encourages the MMRF
Two New Treatments Studied for Relapsed Hodgkin Lymphoma
For Hodgkin lymphoma patients who progress after a stem cell transplant, two new treatments may bring new hope.
7 Ways to Thank Your Caregiver
Breast cancer research in 2010 and the Breast Cancer Deadline 2020
Where are we in breast cancer research?
Another SABCS comes to a close
Why is the San Antonio Breast Cancer Symposium so unique and special?
A disquieting moment: Two steps backwards?
Confessions of a two-time survivor
When living becomes a full-time job
The research decision paradigm shift
